Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and ...

Panmure Liberum holds its 'buy' rating and 32p target as FDA fast-track status adds regulatory momentum to compelling trial ...

UK biotech Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine. The SCOPE study of iSCIB1+, an ...

(RTTNews) - Scancell Holding plc (SCLP) announced that the U.S FDA has cleared its Investigational New Drug Application for a global Phase 3 trial evaluating iSCIB1+ in advanced melanoma. Melanoma ...

Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as ...

Scancell Holdings (GB:SCLP) has released an update. Scancell Holdings has announced that all resolutions at its recent Annual General Meeting have been successfully passed, paving the way for further ...

First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer First-in-human clinical trial in patients with triple negative ...

U.K. biotech Scancell is taking no chances when it comes to carrying out trials of its candidate vaccine for non-small cell lung cancer (NSCLC). The company has joined forces with the Addario Lung ...

Scancell Holdings plc, the developer of Immunobody and Moditope active immunotherapies to treat cancer, announces further positive data from the ongoing phase 2 SCOPE trial of SCIB1/iSCIB1+ Immunobody ...

Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in combination with checkpoint inhibitors has the potential to set the new standard for advanced melanoma Progression-free survival (PFS) ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...